Key Developments: GlaxoSmithKline Pharmaceuticals Ltd (GLAX.NS)

GLAX.NS on National Stock Exchange of India

2,986.25INR
5:22am EST
Price Change (% chg)

Rs6.10 (+0.20%)
Prev Close
Rs2,980.15
Open
Rs2,963.00
Day's High
Rs3,029.15
Day's Low
Rs2,950.05
Volume
5,422
Avg. Vol
17,296
52-wk High
Rs3,247.00
52-wk Low
Rs2,365.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

GlaxoSmithKline Pharmaceuticals Ltd announces change in CFO
Thursday, 6 Nov 2014 07:03am EST 

GlaxoSmithKline Pharmaceuticals Ltd:Appointed Andrew Aristidou as the chief financial officer and executive director of the company from Dec. 01.Mehernosh Kapadia, current chief financial officer and senior executive director will retire from service on Nov. 30 and will cease to be a director of the company from Dec. 01.  Full Article

GlaxoSmithKline Pharmaceuticals Ltd announces change in financial year
Thursday, 6 Nov 2014 03:06am EST 

GlaxoSmithKline Pharmaceuticals Ltd:Decided to change the financial year of the company from Jan. - Dec. to April - March.Accordingly the company’s current financial year shall be for a period of fifteen months that is from Jan. 01, 2014 to March 31, 2015.  Full Article

GlaxoSmithKline Pharmaceuticals Ltd recommends dividend
Tuesday, 18 Feb 2014 02:31am EST 

GlaxoSmithKline Pharmaceuticals Ltd:Recommends the payment of a dividend of 50 Indian Rupees per equity share for FY 2013.  Full Article

GlaxoSmithKline Pharmaceuticals Ltd announces voluntary open offer by GlaxoSmithKline Pte Ltd along with GlaxoSmithkline plc
Sunday, 15 Dec 2013 10:20pm EST 

GlaxoSmithKline Pharmaceuticals Ltd:Says voluntary open offer by GlaxoSmithKline Pte Ltd (the Acquirer) along with GlaxoSmithkline plc in its capacity as person acting in concert (the PAC) with the Acquirer, to the public shareholders of the company to acquire 20,609,774 equity shares (Shares).  Full Article

Fountain Biopharma Inc Signs New Drug Cooperative Agreement with GSK
Tuesday, 6 Aug 2013 03:05am EDT 

Fountain Biopharma Inc announced that it has signed a confidentiality agreement with GlaxoSmithKline Pharmaceuticals Ltd (GSK) to cooperate on new drug FB825 (Anti- CεmX) on August 6, 2013.  Full Article

GlaxoSmithKline Pharmaceuticals Ltd Expands Offering In Digestive Antacid Market-Business Standard
Wednesday, 3 Jul 2013 07:12am EDT 

Business Standard reported that GlaxoSmithKline Pharmaceuticals Ltd is introducing liquid and tablet versions of its Eno brand to strengthen its leadership position in the digestive antacid market in India.  Full Article

GlaxoSmithKline Pharmaceuticals Ltd Recommends Dividend
Tuesday, 19 Feb 2013 03:18am EST 

GlaxoSmithKline Pharmaceuticals Ltd announced that the Board of Directors of the Company at its meeting held on February 19, 2013, inter alia, has recommended a Dividend of INR50 per equity shares (Previous year : INR45 per equity share).  Full Article

GlaxoSmithKline Pharmaceuticals Ltd In JV With Biological E Ltd For Developing Paediatric Vaccine-Economic Times
Tuesday, 29 Jan 2013 03:04am EST 

Economic Times reported that GlaxoSmithKline Pharmaceuticals Ltd has teamed up with Hyderabad-based vaccines company Biological E Ltd for early-stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing markets. Under the equal joint venture (JV) agreement, both companies will develop a six-in-one vaccine for polio and other infectious diseases, reinforcing their commitment to work with the World Health Organisation (WHO) to eradicate polio. The JV, however, will enter phase-1 trial in the next two years. GSK will combine its injectable polio vaccine and Biological E will combine its pentavalent vaccine of tetanus, diphtheria, whooping cough, hepatitis B, haemophilus influenzae type B.  Full Article

CORRECTED-BRIEF-Galapagos says GSK2586184 will not be developed by GSK for oral administration in psoriasis

* GlaxoSmithKline (GSK) (Not GlaxoSmithKline Pharmaceuticals (GSK) ) has informed Galapagos that GSK2586184, a selective JAK1 inhibitor licensed from Galapagos, will not be developed by GSK for oral administration in psoriasis

Search Stocks